10 Stocks with Huge Catalysts on the Horizon

3. Insmed Incorporated (NASDAQ:INSM)

Number of Hedge Fund Holders: 64

Insmed Incorporated (NASDAQ:INSM) holds a position among the list of 10 stocks with huge catalysts on the horizon. The company eyes Brensocatib approval by August 12, and its TPIP Phase 3 and $750 million funding bolsters pipeline momentum.

New Jersey-based company, Insmed Incorporated (NASDAQ:INSM), is a global biopharmaceutical company developing life‑altering therapies for serious and rare diseases. The company targets pulmonary and inflammatory disorders with its pipeline, including Arikayce®, Brensocatib, and TPIP, and has a global presence, with operational regions spanning the United States, Europe, and Japan.

With a PDUFA date set for August 12, 2025, Insmed Incorporated (NASDAQ:INSM) is nearing a pivotal FDA decision for brensocatib. If approved, brensocatib would launch immediately in the U.S. for non-cystic fibrosis bronchiectasis. Positive Phase 2b results for TPIP support planned Phase 3 trials in PAH and PH-ILD, targeting multi-billion-dollar markets.

Also, in June 2025, the company raises $750 million in equity, securing capital for development and commercialization. Multiple clinical readouts (ARIKAYCE and brensocatib in new indications) are expected in 2025–2026. The strong pipeline in respiratory and inflammatory diseases positions the company for transformative growth in the high unmet-need segments.

The strong hedge fund backing, as noted by Insider Monkey, signals growing institutional confidence for Insmed Incorporated (NASDAQ:INSM), suggesting significant upside potential.